June 2013
Volume 54, Issue 15
ARVO Annual Meeting Abstract  |   June 2013
Optimal treatment strategy for Stage 5 Type 2A Idiopathic Macular Telangiectasia with anti-vascular endothelial growth factor (VEGF) agents - When to stop?
Author Affiliations & Notes
  • Sharad Malavade
    Ophthalmology, University of South Florida, Tampa, FL
  • Steven Cohen
    Ophthalmology, University of South Florida, Tampa, FL
  • Footnotes
    Commercial Relationships Sharad Malavade, None; Steven Cohen, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 4930. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Sharad Malavade, Steven Cohen; Optimal treatment strategy for Stage 5 Type 2A Idiopathic Macular Telangiectasia with anti-vascular endothelial growth factor (VEGF) agents - When to stop?. Invest. Ophthalmol. Vis. Sci. 2013;54(15):4930. doi: https://doi.org/.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: To evaluate long term follow-up of patients with Stage 5 (neovascular) Type 2A idiopathic macular telangiectasia treated with anti-vascular endothelial growth factor (VEGF) agents.

Methods: Retrospective review of three cases treated with bevacizumab and subsequently followed for an average 45 months (range 26 months - 61 months). The charts were reviewed to determine presenting symptoms, the baseline visual acuity at time of diagnosis of subretinal neovascular membrane (SRNVM), initial series of treatments with intra-vitreal bevacizumab injections, period of quiescence, recurrence and repeat therapy.

Results: All patients presented with acute vision loss. The average age was 71 years (range 60 years - 78 years) at time of presentation. The average Snellen visual acuity was 20/125 (range 20/50 to 20/200). Signs of neovascularization included pigment epithelial detachment, subretinal fluid and subretinal hemorrhage. Following treatment with intravitreal bevacizumab, each patient’s presenting symptoms abated and the average visual acuity improved to 20/63 (range 20/50 to 20/160). The treatment was stopped when the macula became dry and stable following a treat and extend treatment strategy. In all three patients, recurrent SRNVM was noted after a mean period of 22 months (range 6 months - 41 months) of their last injection. At recurrence, each eye developed similar signs and symptoms to the initial episode. The patients have all responded to re-institution of intravitreal bevacizumab.

Conclusions: It may not be safe to discontinue intravitreal injection of anti-VEFG agents in eyes of patients with neovascular Type 2A macular telangiectasia. Time to recurrence varied from 6 months to 41 months. The optimal treatment strategy for patients with stage 5 Type 2A macular telangiectasia is not known.

Keywords: 462 clinical (human) or epidemiologic studies: outcomes/complications • 585 macula/fovea • 609 neovascularization  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.